+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pulmonary Arterial Hypertension Market by Drug Class (Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostanoids), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution, End User - Global Forecast 2025-2030- Product Image
Pulmonary Arterial Hypertension Market by Drug Class (Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostanoids), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution, End User - Global Forecast 2025-2030- Product Image
Sale

Pulmonary Arterial Hypertension Market by Drug Class (Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostanoids), Route Of Administration (Intravenous, Oral, Subcutaneous), Distribution, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5011141
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pulmonary arterial hypertension (PAH) market is at a pivotal stage, shaped by advancements in therapy, regulatory change, and evolving healthcare priorities. Industry leaders are facing complex challenges alongside new opportunities to optimize care delivery, scale innovation, and address global disparities in disease management.

Market Snapshot: Pulmonary Arterial Hypertension Market Growth

The Pulmonary Arterial Hypertension Market grew from USD 9.12 billion in 2024 to USD 9.77 billion in 2025. It is projected to expand at a CAGR of 7.46%, reaching USD 14.04 billion by 2030.

Scope & Segmentation

This report offers an in-depth analysis of the PAH market across product types, delivery approaches, and end users, while providing clear visibility into geographic differences and key industry participants. Segmentation covers all primary commercial and clinical categories currently driving therapeutic and operational decisions:

  • Drug Class: Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostanoids anchor contemporary clinical practice, with pipeline innovation actively diversifying available options.
  • Route of Administration: Intravenous, oral, and subcutaneous formulations support a continuum of care from acute management to outpatient adherence and convenience.
  • Distribution: Hospital pharmacies, online pharmacies, and retail outlets facilitate drug availability, bridging the transition between inpatient settings and ongoing home-based therapy.
  • End User: Academic and research institutions, specialty clinics, and hospitals play central roles in research, early intervention, and longitudinal patient support.
  • Regions & Countries: The study spans the Americas (including the United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (from the United Kingdom and Germany to South Africa and Egypt), and the Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Industry Participants: The report examines strategic developments among key companies such as Alembic Pharmaceuticals, AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., United Therapeutics Corporation, and others pivotal to PAH therapy and commercialization.

Key Takeaways for Decision-Makers

  • Advances in precision medicine and molecular research are yielding expanded treatment options beyond established drug classes, fueling a more diversified development landscape.
  • Digital health solutions, such as remote monitoring and telemedicine, are being integrated into clinical pathways, enabling adaptive, patient-centered care and enhancing adherence tracking.
  • Stakeholder collaboration across clinicians, payers, and patient advocacy groups is essential for navigating shifting reimbursement frameworks and achieving long-term patient benefit.
  • Localized manufacturing and strategic supply partnerships are becoming critical in response to evolving cost pressures and global sourcing vulnerabilities.
  • Regional diversity significantly defines market access and adoption dynamics, influenced by payer systems, regulatory complexity, and infrastructure variability.
  • Competitive positioning increasingly depends on comprehensive value propositions, combining therapeutic efficacy with service-backed models and robust real-world outcomes.

Tariff Impact on the Pulmonary Arterial Hypertension Supply Chain

United States tariff adjustments enacted in 2025 have introduced new variables within the PAH market’s cost ecosystem. Import duties on active pharmaceutical ingredients and finished therapies increased costs for manufacturers, prompting shifts toward domestic sourcing, longer-term supplier contracts, and the exploration of tariff-exempt manufacturing zones. These adaptations have contributed to supply chain resilience, altered pricing negotiations, and catalyzed value-added patient access initiatives.

Methodology & Data Sources

This executive analysis synthesizes findings from primary interviews with key opinion leaders, comprehensive secondary research (peer-reviewed journals, trial registries, industry reports), and triangulated data validation. Expert consultations encompassed pulmonologists, cardiologists, payers, and patient advocacy representatives, ensuring multi-perspective insights relevant to commercial and clinical decision-makers.

Why This Report Matters

  • Enables senior executives to proactively align product development, market access, and partnership strategies with the evolving needs of the PAH landscape.
  • Provides segmented analysis and actionable intelligence to guide investment decisions and identify high-impact opportunities across technologies, regions, and therapeutic models.
  • Facilitates risk mitigation and sustainable growth through a deep understanding of supply chain, regulatory, and policy drivers shaping future market directions.

Conclusion

The PAH market’s future hinges on synchronized advancements in science, policy, and operational strategy. Leveraging a blend of innovation, stakeholder engagement, and targeted regional adaptation will be essential to delivering sustained clinical and commercial value. This report offers actionable insights to support leadership and strategic planning in a changing healthcare environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of oral soluble guanylate cyclase stimulators expanding treatment options for PAH patients
5.2. Emerging role of personalized medicine approaches based on genetic biomarkers guiding PAH therapy selection
5.3. Increasing integration of remote monitoring technologies and digital therapeutics to improve PAH patient management
5.4. Growing investment in next-generation inhaled formulation platforms targeting pulmonary vasoconstriction in PAH
5.5. Expansion of clinical trials evaluating gene therapy and cell-based interventions for advanced pulmonary hypertension
5.6. Strategic partnerships between biotech firms and academic centers accelerating PAH drug discovery and development
5.7. Rising focus on cost-effectiveness and health economic outcomes shaping reimbursement for PAH therapies
5.8. Surge in real-world evidence studies assessing long-term safety and efficacy of combination PAH treatments
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pulmonary Arterial Hypertension Market, by Drug Class
8.1. Introduction
8.2. Endothelin Receptor Antagonists
8.3. Phosphodiesterase-5 Inhibitors
8.4. Prostanoids
9. Pulmonary Arterial Hypertension Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Pulmonary Arterial Hypertension Market, by Distribution
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Pulmonary Arterial Hypertension Market, by End User
11.1. Introduction
11.2. Academic & Research Institutions
11.3. Clinics
11.4. Hospitals
12. Americas Pulmonary Arterial Hypertension Market
12.1. Introduction
12.2. Mexico
12.3. United States
12.4. Argentina
12.5. Brazil
12.6. Canada
13. Europe, Middle East & Africa Pulmonary Arterial Hypertension Market
13.1. Introduction
13.2. Netherlands
13.3. Italy
13.4. United Kingdom
13.5. France
13.6. Norway
13.7. Turkey
13.8. Saudi Arabia
13.9. South Africa
13.10. Qatar
13.11. Egypt
13.12. Denmark
13.13. Spain
13.14. Nigeria
13.15. Israel
13.16. Germany
13.17. Sweden
13.18. United Arab Emirates
13.19. Finland
13.20. Switzerland
13.21. Poland
13.22. Russia
14. Asia-Pacific Pulmonary Arterial Hypertension Market
14.1. Introduction
14.2. Singapore
14.3. Thailand
14.4. India
14.5. South Korea
14.6. Japan
14.7. Philippines
14.8. Indonesia
14.9. Malaysia
14.10. Vietnam
14.11. China
14.12. Australia
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alembic Pharmaceuticals Limited
15.3.2. AstraZeneca PLC
15.3.3. Aurobindo Pharma Limited
15.3.4. Bayer AG
15.3.5. Boehringer Ingelheim GmbH
15.3.6. Cipla Limited
15.3.7. CMP Pharma, Inc.
15.3.8. Dr. Reddy’s Laboratories Limited
15.3.9. Eli Lilly and Company
15.3.10. Gilead Sciences, Inc.
15.3.11. GlaxoSmithKline PLC
15.3.12. Gossamer Bio, Inc.
15.3.13. Gyre Therapeutics, Inc.
15.3.14. Hikma Pharmaceuticals PLC
15.3.15. Johnson & Johnson Services, Inc.
15.3.16. Lupin Limited
15.3.17. Merck KGaA
15.3.18. Novartis AG
15.3.19. Pfizer, Inc.
15.3.20. Sun Pharmaceutical Industries Limited
15.3.21. Teva Pharmaceutical Industries Ltd.
15.3.22. Torrent Pharmaceuticals Limited
15.3.23. United Therapeutics Corporation
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PULMONARY ARTERIAL HYPERTENSION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. PULMONARY ARTERIAL HYPERTENSION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. PULMONARY ARTERIAL HYPERTENSION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCHAI
FIGURE 24. PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCHSTATISTICS
FIGURE 25. PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCHCONTACTS
FIGURE 26. PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PULMONARY ARTERIAL HYPERTENSION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTANOIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 42. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 51. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 52. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 53. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 54. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 55. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 56. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 57. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 74. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 75. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 78. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 79. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 80. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 86. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 87. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 90. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 91. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 103. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 108. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 109. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 112. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 113. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 116. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 117. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 120. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 128. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 129. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 132. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 133. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 140. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 141. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. NORWAY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 144. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 145. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 148. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 149. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. TURKEY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 152. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 154. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 156. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 164. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 168. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 169. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 172. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 173. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 180. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 181. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. EGYPT PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 184. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 185. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 188. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 189. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. DENMARK PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 192. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 193. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 196. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 197. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 200. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 201. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 204. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 205. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. NIGERIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 208. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 209. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 212. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 213. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. ISRAEL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 220. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 221. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 224. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 225. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 228. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 229. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. SWEDEN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 244. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 245. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FINLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 248. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 249. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 252. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 253. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. SWITZERLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 256. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 257. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 260. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 261. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. POLAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 272. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 281. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 286. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 287. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. SINGAPORE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 290. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 291. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 294. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 295. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 298. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 299. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 300. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 301. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2024 (USD MILLION)
TABLE 302. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025-2030 (USD MILLION)
TABLE 303. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE,

Samples

Loading
LOADING...

Companies Mentioned

  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Cipla Limited
  • CMP Pharma, Inc.
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Gossamer Bio, Inc.
  • Gyre Therapeutics, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
  • United Therapeutics Corporation

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.04 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Endothelin Receptor Antagonist - Pipeline Insight, 2025 - Product Image

Endothelin Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Report and Forecast 2025-2034 - Product Image

Pulmonary Arterial Hypertension Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Pulmonary Arterial Hypertension Market Report 2025 - Product Image

Pulmonary Arterial Hypertension Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 188 Pages
  • Global
From
Pulmonary Arterial Hypertension - Pipeline Insight, 2025 - Product Image

Pulmonary Arterial Hypertension - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From

About the Pulmonary Arterial Hypertension Drug Market

Pulmonary Arterial Hypertension (PAH) is a rare, progressive, and life-threatening form of high blood pressure that affects the arteries in the lungs and the right side of the heart. It is a type of cardiovascular disease, and is treated with a variety of drugs. These drugs are used to reduce symptoms, improve exercise capacity, and slow the progression of the disease. Commonly used drugs include prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. The PAH drug market is a rapidly growing segment of the cardiovascular drug market. It is driven by the increasing prevalence of PAH, the development of new drugs, and the increasing awareness of the disease. The market is expected to continue to grow in the coming years, as new drugs are developed and approved. Some of the major companies in the PAH drug market include Actelion Pharmaceuticals, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.